{"id":11658,"date":"2025-03-26T05:00:27","date_gmt":"2025-03-26T09:00:27","guid":{"rendered":"https:\/\/www.med.unc.edu\/urology\/?p=11658"},"modified":"2025-03-25T12:55:24","modified_gmt":"2025-03-25T16:55:24","slug":"dr-westerman-appointed-to-auas-practice-guidelines-committee-strengthening-unc-urologys-influence-in-national-leadership","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/urology\/dr-westerman-appointed-to-auas-practice-guidelines-committee-strengthening-unc-urologys-influence-in-national-leadership\/","title":{"rendered":"Dr. Westerman Appointed to AUA\u2019s Practice Guidelines Committee, Strengthening UNC Urology\u2019s Influence in National Leadership"},"content":{"rendered":"
\"Dr.<\/a><\/div>\n
\"Dr.<\/a><\/div>\n

UNC Urology proudly announces that Dr. Mary Beth Westerman<\/a>, a newly appointed faculty member, has been selected to serve on the American Urological Association\u2019s (AUA) Practice Guidelines Committee<\/a>, a key subcommittee of the Science & Quality Committee.<\/p>\n

The appointment to the AUA Practice Guidelines Committee represents an exciting step forward for both \u00a0Dr. Westerman and UNC Urology. Her expertise, research acumen, and commitment to evidence-based medicine will contribute to advancing national practice standards and enhancing patient outcomes.<\/p>\n

A Prolific Researcher and Leader in Urologic Oncology<\/h2>\n

Dr. Westerman brings a wealth of experience to UNC Urology, with a distinguished early career dedicated to advancing the treatment of complex urologic cancers, including bladder, kidney, prostate, and testicular cancers. Her research focuses on bladder cancer, clinical trials, minimizing length of stay and enhancing early recovery, as well as quality improvement and process optimization in oncologic care and treatment decision-making.<\/p>\n

She has been a co-investigator on multiple prestigious research grants, including an R01 for bladder cancer treatment and has played a pivotal role in national clinical trials. She serves as the Patient-Reported Outcomes Co-Chair for the ARCHER cooperative trial, which is investigating adaptive chemotherapy and radiation for muscle-invasive bladder cancer. Additionally, she previously served as Site PI for the PCORI-funded CISTO trial (Co-PI: Dr. Angela Smith) and the SWOG-sponsored BRIDGE trial, both aimed at advancing treatments for non-muscle invasive bladder cancer.<\/p>\n

Beyond her research contributions, Dr. Westerman is widely recognized for her leadership and service within the urologic oncology community. She served on the Steering Committee for the Young Urologic Oncologist section of the Society of Urologic Oncology (SUO) and the Board of Directors for the Society of Urologic Oncologists \u2013 Clinical Trials Committee (SUO-CTC).<\/p>\n

Strengthening UNC Urology\u2019s Leadership in the AUA<\/h2>\n

With Dr. Westerman\u2019s new appointment, UNC Urology now has multiple faculty members holding key leadership roles within the AUA\u2019s Science & Quality governance:<\/p>\n